#ariba_ref_name	ref_name	gene	var_only	flag	reads	cluster	ref_len	ref_base_assembled	pc_ident	ctg	ctg_len	ctg_cov	known_var	var_type	var_seq_type	known_var_change	has_known_var	ref_ctg_change	ref_ctg_effect	ref_start	ref_end	ref_nt	ctg_start	ctg_end	ctg_nt	smtls_total_depth	smtls_nts	smtls_nts_depth	var_description	free_text
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	531	14882	16S	1529	1529	99.87	16S.l15.c17.ctg.1	2342	771.0	0	.	n	.	0	A69G	SNP	69	69	A	454	454	G	928	G,A,T	925,2,1	.	.
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	531	14882	16S	1529	1529	99.87	16S.l15.c17.ctg.1	2342	771.0	0	.	n	.	0	C1450T	SNP	1450	1450	C	1835	1835	T	932	T	932	.	.
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	531	14882	16S	1529	1529	99.87	16S.l15.c17.ctg.1	2342	771.0	1	SNP	n	C1184T	0	.	.	1184	1184	C	1569	1569	C	962	C,A	961,1	16S.rDNA_WHO_F_01361c:0:1:C1184T:16S.1184T:E coli C1192T. Resistance to Spectinomycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	25722	23S	2890	2890	99.93	23S.l15.c4.ctg.1	4215	761.9	0	.	n	.	0	T695C	SNP	695	695	T	1274	1274	C	928	C,T,G	924,2,2	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	25722	23S	2890	2890	99.93	23S.l15.c4.ctg.1	4215	761.9	0	.	n	.	0	T1971C	SNP	1971	1971	T	2550	2550	C	904	C,G,A	902,1,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	25722	23S	2890	2890	99.93	23S.l15.c4.ctg.1	4215	761.9	1	SNP	n	A2045G	0	.	.	2045	2045	A	2624	2624	A	820	A,G,T	817,2,1	23S.rDNA_WHO_F_01358c:0:1:A2045G:23S.2045G:E coli A2059G. High-level resistance to Azithromycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	25722	23S	2890	2890	99.93	23S.l15.c4.ctg.1	4215	761.9	1	SNP	n	C2597T	0	.	.	2597	2597	C	3176	3176	C	901	C,T,A,G	897,1,2,1	23S.rDNA_WHO_F_01358c:0:1:C2597T:23S.2597T :E coli C2611T. Low-level resistance to Azithromycin	.
folP.WHO_Y_01480c	folP.WHO_Y_01480c	1	1	27	2380	folP	855	855	100.0	folP.l15.c30.ctg.1	2050	144.6	1	SNP	p	R229S	1	.	.	685	687	AGC	1281	1283	AGC	207;206;203	A;G;C	207;206;203	folP.WHO_Y_01480c:1:1:R229S:folP.228S:Resistance to sulphonamides	.
gyrA.WHO_M_01098	gyrA.WHO_M_01098	1	1	27	5668	gyrA	2751	2751	100.0	gyrA.l15.c4.ctg.1	3998	177.0	1	SNP	p	S91F	1	.	.	271	273	TTC	919	921	TTC	194;195;195	T;T,C;C	194;194,1;195	gyrA.WHO_M_01098:1:1:S91F:gyrA.91F:Resistance to fluoroquinolones	.
gyrA.WHO_M_01098	gyrA.WHO_M_01098	1	1	27	5668	gyrA	2751	2751	100.0	gyrA.l15.c4.ctg.1	3998	177.0	1	SNP	p	G95N	0	.	.	283	285	GGC	931	933	GGC	200;200;200	G;G,A;C	200;199,1;200	gyrA.WHO_M_01098:1:1:G95N:gyrA.95N:Resistance to fluoroquinolones	.
gyrA.WHO_M_01098	gyrA.WHO_M_01098	1	1	27	5668	gyrA	2751	2751	100.0	gyrA.l15.c4.ctg.1	3998	177.0	1	SNP	p	D95G	1	.	.	283	285	GGC	931	933	GGC	200;200;200	G;G,A;C	200;199,1;200	gyrA.WHO_M_01098:1:1:D95G:gyrA.95G:Resistance to fluoroquinolones	.
mtrR.WHO_U_01459	mtrR.WHO_U_01459	1	1	539	2080	mtrR	633	633	99.84	mtrR.l15.c4.ctg.1	1901	136.7	0	.	p	.	0	D79N	NONSYN	235	237	GAT	857	859	AAT	222;222;225	A,C;A,C;T	221,1;221,1;225	.	.
mtrR.WHO_U_01459	mtrR.WHO_U_01459	1	1	539	2080	mtrR	633	633	99.84	mtrR.l15.c4.ctg.1	1901	136.7	1	SNP	p	G45D	0	.	.	133	135	GGC	755	757	GGC	229;226;225	G;G;C	229;226;225	mtrR.WHO_U_01459:1:1:G45D:mtrR.45D:Increased efflux of antimicrobials, e.g. macrolides and b-lactam antimicrobials, that are substrates of the MtrCDE efflux pump	.
mtrR_promoter.WHO_F	mtrR_promoter.WHO_F	0	0	531	1210	mtrR_promoter	250	250	99.6	mtrR_promoter.l15.c4.ctg.1	1467	102.7	0	.	n	.	0	A197.	DEL	197	197	A	734	734	A	242	A	242	.	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	539	5098	parC	2304	2304	99.87	parC.l15.c4.ctg.1	3567	178.5	0	.	p	.	0	E91G	NONSYN	271	273	GAG	925	927	GGG	195;194;198	G;G,A;G,C	195;192,2;197,1	.	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	539	5098	parC	2304	2304	99.87	parC.l15.c4.ctg.1	3567	178.5	1	SNP	p	D86N	0	.	.	256	258	GAC	910	912	GAC	189;187;186	G;A;C	189;187;186	parC.WHO_M_00204c:1:1:D86N:parC.86N:Resistance to fluoroquinolones	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	539	5098	parC	2304	2304	99.87	parC.l15.c4.ctg.1	3567	178.5	1	SNP	p	S87R	0	.	.	259	261	AGT	913	915	AGT	185;182;180	A,G;G;T	184,1;182;180	parC.WHO_M_00204c:1:1:S87R:parC.87R:Resistance to fluoroquinolones	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	539	5098	parC	2304	2304	99.87	parC.l15.c4.ctg.1	3567	178.5	1	SNP	p	S87W	0	.	.	259	261	AGT	913	915	AGT	185;182;180	A,G;G;T	184,1;182;180	parC.WHO_M_00204c:1:1:S87W:parC.87W:Resistance to fluoroquinolones	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	539	5098	parC	2304	2304	99.87	parC.l15.c4.ctg.1	3567	178.5	1	SNP	p	S87I	0	.	.	259	261	AGT	913	915	AGT	185;182;180	A,G;G;T	184,1;182;180	parC.WHO_M_00204c:1:1:S87I:parC.87I:Resistance to fluoroquinolones	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	539	5098	parC	2304	2304	99.87	parC.l15.c4.ctg.1	3567	178.5	1	SNP	p	S88P	0	.	.	262	264	TCC	916	918	TCC	184;183;183	T;C;C,A	184;183;182,1	parC.WHO_M_00204c:1:1:S88P:parC.88P:Resistance to fluoroquinolones	.
parE.WHO_F_01528c	parE.WHO_F_01528c	1	1	539	4356	parE	1986	1986	99.95	parE.l15.c4.ctg.1	3246	167.5	0	.	p	.	0	R427H	NONSYN	1279	1281	CGC	1920	1922	CAC	227;227;225	C,T;A,G;C	226,1;226,1;225	.	.
parE.WHO_F_01528c	parE.WHO_F_01528c	1	1	539	4356	parE	1986	1986	99.95	parE.l15.c4.ctg.1	3246	167.5	1	SNP	p	G410V	0	.	.	1228	1230	GGC	1869	1871	GGC	258;255;253	G;G;C	258;255;253	parE.WHO_F_01528c:1:1:G410V:parE.410V:Resistance to fluoroquinolones	.
penA.44.001	penA.44.001	1	1	27	4018	penA	1749	1749	100.0	penA.l15.c4.ctg.1	3116	161.1	1	SNP	p	A311V	0	.	.	931	933	GCA	1571	1573	GCA	235;236;239	G;C,G;A	235;235,1;239	penA.44.001:1:1:A311V:penA.311V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.44.001	penA.44.001	1	1	27	4018	penA	1749	1749	100.0	penA.l15.c4.ctg.1	3116	161.1	1	SNP	p	I312M	0	.	.	934	936	ATC	1574	1576	ATC	239;237;237	A;T,C;C,T	239;236,1;236,1	penA.44.001:1:1:I312M:penA.312M:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.44.001	penA.44.001	1	1	27	4018	penA	1749	1749	100.0	penA.l15.c4.ctg.1	3116	161.1	1	SNP	p	V316P	0	.	.	946	948	GTG	1586	1588	GTG	228;230;231	G;T;G	228;230;231	penA.44.001:1:1:V316P:penA.316P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.44.001	penA.44.001	1	1	27	4018	penA	1749	1749	100.0	penA.l15.c4.ctg.1	3116	161.1	1	SNP	p	V316T	0	.	.	946	948	GTG	1586	1588	GTG	228;230;231	G;T;G	228;230;231	penA.44.001:1:1:V316T:penA.316T:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.44.001	penA.44.001	1	1	27	4018	penA	1749	1749	100.0	penA.l15.c4.ctg.1	3116	161.1	1	SNP	p	T484S	0	.	.	1450	1452	ACC	2090	2092	ACC	218;218;217	A,C;C,A;C	217,1;217,1;217	penA.44.001:1:1:T484S:penA.483S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.44.001	penA.44.001	1	1	27	4018	penA	1749	1749	100.0	penA.l15.c4.ctg.1	3116	161.1	1	SNP	p	T502V	0	.	.	1504	1506	ACG	2144	2146	ACG	206;206;203	A,G,C;C,A;G,T	204,1,1;205,1;202,1	penA.44.001:1:1:T502V:penA.501V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.44.001	penA.44.001	1	1	27	4018	penA	1749	1749	100.0	penA.l15.c4.ctg.1	3116	161.1	1	SNP	p	T502P	0	.	.	1504	1506	ACG	2144	2146	ACG	206;206;203	A,G,C;C,A;G,T	204,1,1;205,1;202,1	penA.44.001:1:1:T502P:penA.501P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.44.001	penA.44.001	1	1	27	4018	penA	1749	1749	100.0	penA.l15.c4.ctg.1	3116	161.1	1	SNP	p	G543S	0	.	.	1627	1629	GGC	2267	2269	GGC	233;233;233	G,T;G;C,T	232,1;233;232,1	penA.44.001:1:1:G543S:penA.542S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.44.001	penA.44.001	1	1	27	4018	penA	1749	1749	100.0	penA.l15.c4.ctg.1	3116	161.1	1	SNP	p	G546S	0	.	.	1636	1638	GGC	2276	2278	GGC	233;232;231	G;G;C	233;232;231	penA.44.001:1:1:G546S:penA.545S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.44.001	penA.44.001	1	1	27	4018	penA	1749	1749	100.0	penA.l15.c4.ctg.1	3116	161.1	1	SNP	p	L552S	0	.	.	1654	1656	CTG	2294	2296	CTG	238;240;241	C,T;T,C;G	237,1;239,1;241	penA.44.001:1:1:L552S:penA.551S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
ponA.WHO_G_00106	ponA.WHO_G_00106	1	1	27	5810	ponA	2397	2397	100.0	ponA.l6.c4.ctg.1	3679	197.3	1	SNP	p	L421P	1	.	.	1261	1263	CCG	1930	1932	CCG	229;228;228	C;C,T;G,C	229;227,1;227,1	ponA.WHO_G_00106:1:1:L421P:ponA.421P:High-level chromosomally-mediated penicillin resistance	.
porA.NCCP11945	porA.NCCP11945	1	0	531	2748	porA	1146	1146	99.65	porA.l15.c30.ctg.1	2512	136.6	0	.	p	.	0	M83fs	FSHIFT	247	247	A	905	905	C	201	C,G	200,1	.	.
porB1a.WHO_F_02106	porB1a.WHO_F_02106	1	0	528	278	porB1a	984	152	93.42	porB1a.l15.c17.ctg.4	155	48.4	0	.	p	.	0	V258L	NONSYN	772	774	GTA	13	15	TTA	26;28;30	T;T;A	26;28;30	.	.
porB1a.WHO_F_02106	porB1a.WHO_F_02106	1	0	528	278	porB1a	984	152	93.42	porB1a.l15.c17.ctg.4	155	48.4	0	.	p	.	0	Y273H	NONSYN	817	819	TAT	58	60	CAT	60;60;60	C;A;T	60;60;60	.	.
porB1a.WHO_F_02106	porB1a.WHO_F_02106	1	0	528	278	porB1a	984	152	93.42	porB1a.l15.c17.ctg.4	155	48.4	0	.	p	.	0	D274S	NONSYN	820	822	GAT	61	63	AGT	60;60;60	A;G;T	60;60;60	.	.
porB1a.WHO_F_02106	porB1a.WHO_F_02106	1	0	528	278	porB1a	984	152	93.42	porB1a.l15.c17.ctg.4	155	48.4	0	.	p	.	0	N277Y	NONSYN	829	831	AAC	70	72	TAC	60;60;60	T;A;C	60;60;60	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	3146	porB1b	1047	1047	99.04	porB1b.l15.c30.ctg.1	1638	229.0	0	.	p	.	0	T26A	NONSYN	76	78	ACC	531	533	GCC	261;259;258	G;C;C	261;259;258	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	3146	porB1b	1047	1047	99.04	porB1b.l15.c30.ctg.1	1638	229.0	0	.	p	.	0	N38E	NONSYN	112	114	AAT	567	569	GAA	270;269;266	G,A;A;A	269,1;269;266	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	3146	porB1b	1047	1047	99.04	porB1b.l15.c30.ctg.1	1638	229.0	0	.	p	.	0	N124S	NONSYN	370	372	AAT	825	827	AGT	226;227;227	A;G,A;T,C	225;225,1;226,1	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	3146	porB1b	1047	1047	99.04	porB1b.l15.c30.ctg.1	1638	229.0	0	.	p	.	0	N134D	NONSYN	400	402	AAT	855	857	GAT	225;223;218	G;A;T,G	225;223;217,1	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	3146	porB1b	1047	1047	99.04	porB1b.l15.c30.ctg.1	1638	229.0	0	.	p	.	0	P175S	NONSYN	523	525	CCA	978	980	TCA	281;279;280	T;C;A	281;279;280	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	3146	porB1b	1047	1047	99.04	porB1b.l15.c30.ctg.1	1638	229.0	0	.	p	.	0	A218V	NONSYN	652	654	GCC	1107	1109	GTC	263;263;260	G,T,A;T;C,G	261,1,1;263;259,1	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	3146	porB1b	1047	1047	99.04	porB1b.l15.c30.ctg.1	1638	229.0	0	.	p	.	0	F222S	NONSYN	664	666	TTT	1119	1121	TCT	255;256;258	T;C,T,A,G;T	255;252,1,2,1;258	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	3146	porB1b	1047	1047	99.04	porB1b.l15.c30.ctg.1	1638	229.0	0	.	p	.	0	E328A	NONSYN	982	984	GAA	1437	1439	GCA	275;276;276	G;C,T;A	275;275,1;276	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	3146	porB1b	1047	1047	99.04	porB1b.l15.c30.ctg.1	1638	229.0	1	SNP	p	G120K	1	.	.	358	360	AAG	813	815	AAG	207;208;209	A;A;G	206;207;208	porB1b.WHO_V_02265c:1:1:G120K:porB1b.120K:G101K. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	3146	porB1b	1047	1047	99.04	porB1b.l15.c30.ctg.1	1638	229.0	1	SNP	p	D121N	0	.	.	361	363	GAC	816	818	GAC	210;214;218	G;AC,A;C	209;213,1;217	porB1b.WHO_V_02265c:1:1:D121N:porB1b.121N:A102N. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	3146	porB1b	1047	1047	99.04	porB1b.l15.c30.ctg.1	1638	229.0	1	SNP	p	A121D	1	.	.	361	363	GAC	816	818	GAC	210;214;218	G;AC,A;C	209;213,1;217	porB1b.WHO_V_02265c:1:1:A121D:porB1b.121D:A102D. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
rpoB.WHO_F_02153c	rpoB.WHO_F_02153c	1	1	27	10144	rpoB	4179	4179	100.0	rpoB.l15.c4.ctg.1	5433	233.2	1	SNP	p	H553N	0	.	.	1657	1659	CAT	2277	2279	CAT	246;245;244	C,A;A,G;T	245,1;244,1;244	rpoB.WHO_F_02153c:1:1:H553N:rpoB.553N:H552N. High-level resistance to Rifampicin	.
rpsJ.WHO_Y_02241	rpsJ.WHO_Y_02241	1	1	27	1560	rpsJ	312	312	100.0	rpsJ.l15.c4.ctg.1	1425	136.3	1	SNP	p	V57M	1	.	.	169	171	ATG	745	747	ATG	256;257;259	A;T;G,A	256;257;257,2	rpsJ.WHO_Y_02241:1:1:V57M:rpsJ.57M:Chromosomally-mediated resistance to tetracyclines	.
